Editas Medicine Announces Third Quarter 2024 Results and Business Updates
Editas Medicine (EDIT) reported Q3 2024 financial results, highlighting a net loss of $62.1 million ($0.75 per share). The company achieved preclinical proof of concept for in vivo HBG1/2 editing in HSPCs using proprietary targeted LNP technology for sickle cell disease and beta thalassemia treatment. Cash position stands at $265.1 million, expected to fund operations into Q2 2026. The company secured a $57 million upfront payment from DRI Healthcare Trust through the sale of certain future license fees. Research and development expenses increased to $47.6 million, while revenues decreased to $0.1 million.
Editas Medicine (EDIT) ha riportato i risultati finanziari del terzo trimestre del 2024, evidenziando una perdita netta di 62,1 milioni di dollari (0,75 dollari per azione). L'azienda ha raggiunto la prova di concetto preclinica per l'editing in vivo di HBG1/2 in HSPC utilizzando una tecnologia proprietaria di LNP mirata per il trattamento della malattia falciforme e della beta talassemia. La posizione di cassa ammonta a 265,1 milioni di dollari, il che si prevede sosterrà le operazioni fino al secondo trimestre del 2026. L'azienda ha ottenuto un pagamento anticipato di 57 milioni di dollari da DRI Healthcare Trust attraverso la vendita di alcune future royalty di licenza. Le spese di ricerca e sviluppo sono aumentate a 47,6 milioni di dollari, mentre i ricavi sono diminuiti a 0,1 milioni di dollari.
Editas Medicine (EDIT) informó los resultados financieros del tercer trimestre de 2024, destacando una pérdida neta de 62,1 millones de dólares (0,75 dólares por acción). La compañía logró una prueba de concepto preclínica para la edición in vivo de HBG1/2 en HSPC utilizando una tecnología LNP dirigida de propiedad para el tratamiento de la enfermedad de células falciformes y la beta talasemia. La posición de efectivo se sitúa en 265,1 millones de dólares, que se espera financie las operaciones hasta el segundo trimestre de 2026. La empresa aseguró un pago por adelantado de 57 millones de dólares del DRI Healthcare Trust a través de la venta de ciertas futuras tarifas de licencia. Los gastos de investigación y desarrollo aumentaron a 47,6 millones de dólares, mientras que los ingresos disminuyeron a 0,1 millones de dólares.
Editas Medicine (EDIT)는 2024년 3분기 재무 결과를 발표하며 6,210만 달러 (주당 0.75 달러)의 순손실을 보고했습니다. 이 회사는 낫 모양 적혈구 질환 및 베타 지중해빈혈 치료를 위한 독점적인 표적 LNP 기술을 사용하여 HSPC에서 in vivo HBG1/2 편집에 대한 전임상 개념 증명을 달성했습니다. 현금 보유액은 2억 6,510만 달러로, 2026년 2분기까지 운영 자금을 지원할 것으로 예상됩니다. 이 회사는 DRI Healthcare Trust로부터 향후 라이센스 수수료의 일부 판매를 통해 5,700만 달러의 선급금을 확보했습니다. 연구 및 개발 비용은 4,760만 달러로 증가했으며, 수익은 10만 달러로 감소했습니다.
Editas Medicine (EDIT) a annoncé les résultats financiers du troisième trimestre 2024, mettant en évidence une perte nette de 62,1 millions de dollars (0,75 dollar par action). L'entreprise a réalisé une preuve de concept préclinique pour l'édition in vivo de HBG1/2 dans les HSPC en utilisant une technologie LNP ciblée propriétaire pour le traitement de la drépanocytose et de la bêta-thalassémie. La position de trésorerie s'élève à 265,1 millions de dollars, ce qui devrait financer les opérations jusqu'au deuxième trimestre 2026. L'entreprise a sécurisé un paiement initial de 57 millions de dollars de DRI Healthcare Trust grâce à la vente de certaines redevances de licence futures. Les dépenses de recherche et développement ont augmenté à 47,6 millions de dollars, tandis que les revenus ont diminué à 0,1 million de dollars.
Editas Medicine (EDIT) hat die finanziellen Ergebnisse des dritten Quartals 2024 bekannt gegeben und dabei einen Nettoverlust von 62,1 Millionen Dollar (0,75 Dollar pro Aktie) hervorgehoben. Das Unternehmen erzielte einen präklinischen Nachweis des Konzepts für die in vivo Bearbeitung von HBG1/2 in HSPCs unter Verwendung einer proprietären zielgerichteten LNP-Technologie zur Behandlung von Sichelzellenanämie und Betatalassämie. Die liquide Mittel belaufen sich auf 265,1 Millionen Dollar, was voraussichtlich ausreicht, um die Betriebsabläufe bis zum zweiten Quartal 2026 zu finanzieren. Das Unternehmen sicherte sich eine Vorauszahlung von 57 Millionen Dollar von DRI Healthcare Trust durch den Verkauf bestimmter zukünftiger Lizenzgebühren. Die Forschungs- und Entwicklungskosten stiegen auf 47,6 Millionen Dollar, während die Einnahmen auf 0,1 Millionen Dollar sanken.
- Secured $57 million non-dilutive capital through DRI Healthcare Trust deal
- Strong cash position of $265.1 million expected to fund operations into Q2 2026
- Achieved preclinical proof of concept for in vivo HBG1/2 editing
- Net loss increased to $62.1 million vs $45.0 million in prior year
- Revenue decreased to $0.1 million from $5.3 million year-over-year
- R&D expenses increased by $7.1 million to $47.6 million
- G&A expenses increased by $3.1 million to $18.1 million
Insights
The Q3 results reveal significant financial developments and strategic positioning. The company reported a
Key financial metrics show increased R&D expenses at
The achievement of in vivo preclinical proof of concept for HBG1/2 editing in HSPCs using proprietary targeted LNP technology marks a significant scientific milestone. This breakthrough positions Editas to potentially develop first-in-class in vivo treatments for both sickle cell disease and beta thalassemia.
The RUBY trial's progression with 28 dosed patients and upcoming data presentation at ASH indicates strong clinical momentum. The completion of enrollment in both adult and adolescent cohorts for the Phase 1/2/3 RUBY trial, coupled with ongoing EdiTHAL trial progress, suggests a robust clinical development pipeline.
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia
On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December
Company to provide an update on its in vivo progress and pipeline development in 1Q 2025
Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI and the retained portions of the payments payable under the license agreement with Vertex, to fund operating expenses and capital expenditures into the second quarter of 2026
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the third quarter 2024 and provided business updates.
“Achieving preclinical proof of concept of HBG1/2 editing in HSPCs using our proprietary targeted LNP, puts us on a clear path to develop a potentially first- and best-in-class in vivo gene edited medicine for the treatment of sickle cell disease and beta thalassemia,” commented Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. “As we continue our process to partner or out-license reni-cel, we also look forward to sharing a substantial clinical update from the RUBY trial of reni-cel, a potentially best-in-class cell therapy for the treatment of sickle cell disease, at ASH in December.”
“I am proud of the Editas team’s work and our advancement in 2024 as we move closer to achieving our vision of becoming a leader in in vivo programmable gene editing medicine,” added Dr. O’Neill.
Recent Achievements and Outlook
Ex Vivo Hemoglobinopathies
- Reni-cel (renizgamglogene autogedtemcel, previously EDIT-301) Partnering/Out-licensing
- The Company has engaged Moelis & Company LLC, a leading global independent investment bank, to lead the global process to partner or out-license reni-cel.
- Reni-cel for Severe Sickle Cell Disease (SCD)
- The Company will present a substantive RUBY clinical trial update of 28 patients with considerable clinical follow-up at the American Society of Hematology (ASH) Annual Meeting and Exposition, December 7-10, 2024.
- Dataset will include safety data and efficacy data, including hematology parameters, vaso-occlusive events (VOEs), and patient reported outcomes (PROs).
- The Company continues to dose adult patients in the RUBY trial and has dosed 28 patients to date.
- The Company continues to manufacture drug product for the initial adolescent cohort patients and schedule dosing.
- As previously announced, the Company has completed enrollment of the adult and adolescent cohorts of the Phase 1/2/3 RUBY trial for SCD.
- The Company will present a substantive RUBY clinical trial update of 28 patients with considerable clinical follow-up at the American Society of Hematology (ASH) Annual Meeting and Exposition, December 7-10, 2024.
- Reni-cel for Transfusion-dependent Beta Thalassemia (TDT)
- The Company is on-track to present additional clinical data from the EdiTHAL trial by year-end 2024.
- As previously announced, the Company completed enrollment of the adult cohort of the EdiTHAL trial for TDT and continues to dose patients.
In Vivo Medicines
- In vivo Preclinical Proof of Concept Achieved: Hematopoietic Stem and Progenitor Cell (HSPC) Editing
- As disclosed on October 22, the Company established in vivo preclinical proof of concept for the development of an in vivo medicine for sickle cell disease and beta thalassemia by demonstrating in vivo hematopoietic stem and progenitor cell (HSPC) editing of HBG1/2 promoter utilizing a novel, Editas-proprietary targeted lipid nanoparticle (tLNP) for extrahepatic tissue delivery in a humanized mouse model (mice engrafted with human hematopoietic stem cells).
- The Company will provide an update on its in vivo progress and pipeline development in 1Q 2025.
- The Company continues to pursue an in vivo strategy and approach aimed at driving functional upregulation of gene expression to address loss of function or deleterious mutations.
- Additional in vivo Targets
- Editas Medicine and Genevant Sciences entered into a collaboration and nonexclusive license agreement to combine Editas’ CRISPR Cas12a genome editing systems with Genevant’s proprietary LNP technology in the development of in vivo gene editing medicines directed to functional upregulation of two liver targets.
Business Development
- On October 3, 2024, Editas Medicine announced the sale of certain future license fees and other payments owed to the Company under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of
$57 million . The upfront cash payment brings non-dilutive capital to Editas Medicine, helping enable further pipeline development and related strategic priorities. - The Company ended the third quarter 2024 with approximately
$265.1 million of cash, cash equivalents, and marketable securities, or approximately$322.1 million following receipt of the upfront cash payment from DRI.
Third Quarter 2024 Financial Results
Cash, cash equivalents, and marketable securities as of September 30, 2024, were
Third Quarter 2024
- For the three months ended September 30, 2024, net loss attributable to common stockholders was
$62.1 million , or$0.75 per share, compared to net loss of$45.0 million , or$0.55 per share, for the same period in 2023. - Collaboration and other research and development revenues decreased to
$0.1 million for the three months ended September 30, 2024, compared to$5.3 million for the same period in 2023. The decrease is primarily attributable to the receipt in the 2023 period of the upfront payment for the non-exclusive license to Vor Bio. - Research and development expenses increased by
$7.1 million to$47.6 million for the three months ended September 30, 2024, compared to$40.5 million for the same period in 2023. The increase is primarily related to clinical and manufacturing costs related to the accelerated progression of the Company’s reni-cel program as well as costs attributable to in vivo research and discovery. - General and administrative expenses increased by
$3.1 million to$18.1 million for the three months ended September 30, 2024, compared to$15.0 million for the same period in 2023. The increase is primarily attributable to increased employee-related expenses related to increased headcount to support business operations due to the progression of reni-cel program.
Upcoming Events
Editas Medicine plans to participate in the following scientific and medical conference:
- American Society of Hematology (ASH) Annual Meeting and Exposition
December 7-10, 2024
San Diego, CA
Editas Medicine plans to participate in the following investor events:
- Guggenheim's Inaugural Healthcare Innovation Conference
November 12, 2024
Boston, MA
- Stifel 2024 Healthcare Conference
November 19, 2024
New York, NY
- 7th Annual Evercore ISI HealthCONx Conference
December 3, 2024
Coral Gables, FL
No 3Q Conference Call
The Company is not hosting a conference call this quarter given it recently held a Strategic Update Webinar on October 22, 2024. A replay of the webinar is available in the Investors section of the Editas Medicine website at https://ir.editasmedicine.com/events-and-presentations.
About Editas Medicine
As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the Company’s intent to partner or out-license reni-cel and any benefits resulting therefrom, the initiation, timing, progress and results of the Company’s preclinical and clinical studies and its research and development programs, the timing for the Company’s receipt and presentation of data from its clinical trials and preclinical studies, including providing an update on its in vivo progress and pipeline development in the first quarter of 2025 and presenting additional clinical data from the RUBY trial at the ASH Annual Meeting and Exposition and from the EdiTHAL trial by year-end 2024, the potential of, and expectations for, the Company’s product candidates, including any in vivo gene edited medicines the Company may develop, the timing or likelihood of regulatory filings and approvals, and the Company’s expectations regarding cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials, including the RUBY and EdiTHAL trials, and clinical development of the Company’s product candidates, including reni-cel; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
| EDITAS MEDICINE, INC. Consolidated Statement of Operations (amounts in thousands, except share and per share data) (Unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Collaboration and other research and development revenues | $ | 61 | $ | 5,336 | $ | 1,710 | $ | 18,074 | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 47,639 | 40,512 | 150,636 | 108,095 | |||||||||||
| General and administrative | 18,088 | 14,987 | 55,633 | 55,198 | |||||||||||
| Total operating expenses | 65,727 | 55,499 | 206,269 | 163,293 | |||||||||||
| Operating loss | (65,666 | ) | (50,163 | ) | (204,559 | ) | (145,219 | ) | |||||||
| Other income, net: | |||||||||||||||
| Other income (expense), net | (5 | ) | — | — | (1,590 | ) | |||||||||
| Interest income, net | 3,530 | 5,144 | 12,861 | 12,464 | |||||||||||
| Total other income, net | 3,525 | 5,144 | 12,861 | 10,874 | |||||||||||
| Net loss | $ | (62,141 | ) | $ | (45,019 | ) | $ | (191,698 | ) | $ | (134,345 | ) | |||
| Net loss per share, basic and diluted | (0.75 | ) | (0.55 | ) | (2.33 | ) | (1.81 | ) | |||||||
| Weighted-average common shares outstanding, basic and diluted | 82,485,199 | 81,648,250 | 82,245,679 | 74,029,645 | |||||||||||
| EDITAS MEDICINE, INC. Selected Consolidated Balance Sheet Items (amounts in thousands) (Unaudited) | |||||
| September 30, | December 31, | ||||
| 2024 | 2023 | ||||
| Cash, cash equivalents, and marketable securities | $ | 265,088 | $ | 427,135 | |
| Working capital | 198,786 | 277,612 | |||
| Total assets | 327,567 | 499,153 | |||
| Deferred revenue, net of current portion | 54,204 | 60,667 | |||
| Total stockholders' equity | 175,634 | 349,097 | |||
FAQ
What was Editas Medicine's (EDIT) net loss in Q3 2024?
How much cash does Editas Medicine (EDIT) have as of Q3 2024?
What was the value of the DRI Healthcare Trust deal for Editas Medicine (EDIT)?
How long will Editas Medicine's (EDIT) current cash runway last?
